Patterns and Disparities in Human Papillomavirus (HPV) Vaccine Uptake for Young Female Adolescents among U.S. States: NIS-Teen (2008-2016).
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
07
09
2019
revised:
09
11
2019
accepted:
23
04
2020
pubmed:
30
4
2020
medline:
16
9
2021
entrez:
30
4
2020
Statut:
ppublish
Résumé
Several studies have reported differential vaccine uptake outcomes that are associated with sociodemographic and socioeconomic characteristics, as well as provider type. However, none has examined a trend over a multiple-year span. In this study, we utilize a longitudinal data-based approach to examine state-level human papillomavirus (HPV) vaccine trends and their influences over time. We analyzed National Immunization Survey - Teen data (2008-2016) to estimate HPV vaccine initiation rate in young female adolescent ages 13-17 years old among U.S. States. We identified growth patterns using the latent class growth method and explored state-level characteristics, including socioeconomic and sociodemographic attributes, and health legislation and policy-related programs among patterns. We identified three growth patterns, which showed gradually increasing vaccination trends but different baseline HPV uptake rates (high, moderate, low). States within Pattern 1 (highest HPV vaccination rates) included the lowest percentage of families with incomes below federal poverty level, the highest percentage of bachelor's degree or higher, and the lowest number of uninsured, while states within Pattern 3 (lowest HPV vaccination rates) included families with socioeconomic attributes along the opposite end of the spectrum. Latent class growth models are an effective tool to be able to capture health disparities in heterogeneity among states in relation to HPV vaccine uptake trajectories. These findings might lead to designing and implementing effective interventions and changes in policies and health care coverage to promote HPV vaccination uptake for states represented under the lowest trajectory pattern.
Sections du résumé
BACKGROUND
Several studies have reported differential vaccine uptake outcomes that are associated with sociodemographic and socioeconomic characteristics, as well as provider type. However, none has examined a trend over a multiple-year span. In this study, we utilize a longitudinal data-based approach to examine state-level human papillomavirus (HPV) vaccine trends and their influences over time.
METHODS
We analyzed National Immunization Survey - Teen data (2008-2016) to estimate HPV vaccine initiation rate in young female adolescent ages 13-17 years old among U.S. States. We identified growth patterns using the latent class growth method and explored state-level characteristics, including socioeconomic and sociodemographic attributes, and health legislation and policy-related programs among patterns.
RESULTS
We identified three growth patterns, which showed gradually increasing vaccination trends but different baseline HPV uptake rates (high, moderate, low). States within Pattern 1 (highest HPV vaccination rates) included the lowest percentage of families with incomes below federal poverty level, the highest percentage of bachelor's degree or higher, and the lowest number of uninsured, while states within Pattern 3 (lowest HPV vaccination rates) included families with socioeconomic attributes along the opposite end of the spectrum.
CONCLUSIONS
Latent class growth models are an effective tool to be able to capture health disparities in heterogeneity among states in relation to HPV vaccine uptake trajectories.
IMPACT
These findings might lead to designing and implementing effective interventions and changes in policies and health care coverage to promote HPV vaccination uptake for states represented under the lowest trajectory pattern.
Identifiants
pubmed: 32345710
pii: 1055-9965.EPI-19-1103
doi: 10.1158/1055-9965.EPI-19-1103
pmc: PMC7415186
mid: NIHMS1605305
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1458-1467Subventions
Organisme : NCI NIH HHS
ID : P50 CA098252
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Am J Public Health. 2018 Apr;108(4):493-499
pubmed: 29470122
BMJ Open. 2018 Apr 20;8(4):e019206
pubmed: 29678965
Vaccine. 2011 Jan 29;29(5):890-5
pubmed: 20056186
Virology. 2013 Oct;445(1-2):2-10
pubmed: 23683837
Vaccine. 2012 May 21;30(24):3546-56
pubmed: 22480928
Dev Psychol. 2009 May;45(3):652-76
pubmed: 19413423
J Community Health. 2020 Apr;45(2):278-287
pubmed: 31520188
J Community Health. 2017 Jun;42(3):522-532
pubmed: 27778139
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086
pubmed: 25925419
Biostatistics. 2002 Dec;3(4):459-75
pubmed: 12933592
MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405-1408
pubmed: 27977643
Pediatrics. 2013 Dec;132(6):1037-46
pubmed: 24190677
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24
pubmed: 17380109
Vaccine. 2018 Jun 7;36(24):3498-3504
pubmed: 29752025
Pediatrics. 2008 Oct;122(4):718-25
pubmed: 18829793
Vaccine. 2013 Jun 10;31(26):2816-21
pubmed: 23602667
BMC Public Health. 2017 Jul 14;18(1):19
pubmed: 28709420
Hum Vaccin Immunother. 2016 Jun 2;12(6):1615-22
pubmed: 27152418
J Cogn Dev. 2010;11(2):121-136
pubmed: 21743795
J Pediatr Psychol. 2014 Mar;39(2):188-203
pubmed: 24277770
Contemp Clin Trials. 2011 Nov;32(6):818-28
pubmed: 21762787
Vaccine. 2016 Feb 24;34(9):1187-92
pubmed: 26812078
Am J Prev Med. 2011 Oct;41(4):428-33
pubmed: 21961471
Risk Manag Healthc Policy. 2017 Mar 13;10:29-32
pubmed: 28331378
MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1705-8
pubmed: 22189893
Am J Public Health. 2016 Jan;106(1):172-7
pubmed: 26562114
Psychol Methods. 2003 Sep;8(3):369-77; discussion 384-93
pubmed: 14596497
Health Educ Behav. 2013 Oct;40(5):544-51
pubmed: 23104978
Front Oncol. 2015 Oct 13;5:223
pubmed: 26528435
Vaccine. 2018 May 31;36(23):3381-3386
pubmed: 29735321
Vital Health Stat 1. 2017 Dec;(61):1-107
pubmed: 29466229
Struct Equ Modeling. 2014 Jan 1;21(4):534-552
pubmed: 25328371
MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):909-917
pubmed: 30138305
Sex Transm Dis. 2013 Mar;40(3):187-93
pubmed: 23403598
Int J Behav Dev. 2009;33(6):565-576
pubmed: 23885133
BMC Public Health. 2019 Feb 28;19(1):246
pubmed: 30819149
Ann Fam Med. 2015 Jul-Aug;13(4):354-60
pubmed: 26195681
Papillomavirus Res. 2016 Dec;2:46-51
pubmed: 29074185
Vaccine. 2012 Nov 20;30 Suppl 5:F55-70
pubmed: 23199966
Hum Vaccin Immunother. 2013 Dec;9(12):2643-8
pubmed: 24247148
Cancer. 2008 Nov 15;113(10 Suppl):2841-54
pubmed: 18980203
J Pediatr Psychol. 2014 Mar;39(2):174-87
pubmed: 24277769
Pediatrics. 2015 Jul;136(1):80-8
pubmed: 26034242